title: Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice.
abstract: Cyclooxygenase (COX) enzyme expression is elevated in human and rodent lung tumors, and non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin reduce lung tumor formation in mice. These observations, along with the well-characterized protection that NSAID treatment engenders for colon cancer, have prompted clinical trials testing whether celecoxib, a COX-2-specific inhibitor, can prevent lung cancer development in populations at high risk. Protection by celecoxib in murine models of pulmonary inflammation and lung tumorigenesis has not yet been evaluated, however, and we now report such studies. Chronic administration of butylated hydroxytoluene (BHT) to mice stimulates pulmonary inflammation characterized by vascular leakage and macrophage infiltration into the air spaces, increased PGE2 production, and translocation of 5-lipoxygenase (5-LO) from the cytosol to the particulate fraction. Dietary celecoxib limited macrophage infiltration, abrogated PGE2 production and reduced particulate 5-LO content. Celecoxib and aspirin were ineffective at preventing lung tumorigenesis in a two-stage carcinogenesis protocol in which 3-methylcholanthrene administration is followed by chronic BHT. Celecoxib also did not reduce the multiplicity of lung tumors after induction by urethane; lung tumors in celecoxib-treated mice were larger than those in mice that did not receive celecoxib. Tumors induced in celecoxib-fed mice contained 60% less PGE2 than tumors in mice fed control diets, so reducing lung PGE2 levels was insufficient to prevent lung tumor formation. As the production of eicosanoids in addition to PGE2 is also inhibited by celecoxib, and as celecoxib has COX-independent interactions, its effects on tumor formation may vary in different organ systems.
authors.affiliation: Department of Pharmaceutical Sciences, University of Colorado Cancer Center, Denver CO 80262, USA.
authors.forename: Lori R
authors.initials: LR
authors.lastname: Kisley
authors.forename: Bradley S
authors.initials: BS
authors.lastname: Barrett
authors.forename: Lori D
authors.initials: LD
authors.lastname: Dwyer-Nield
authors.forename: Alison K
authors.initials: AK
authors.lastname: Bauer
authors.forename: David C
authors.initials: DC
authors.lastname: Thompson
authors.forename: Alvin M
authors.initials: AM
authors.lastname: Malkinson
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002084:Butylated Hydroxytoluene; D000068579:Celecoxib; D007249:Inflammation; D008171:Lung Diseases / Q000517:prevention & control*; D008175:Lung Neoplasms / Q000139:chemically induced / Q000473:pathology*; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D008807:Mice, Inbred BALB C; D011720:Pyrazoles; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D011720:Pyrazoles; D013449:Sulfonamides; D002084:Butylated Hydroxytoluene; D000068579:Celecoxib